145 related articles for article (PubMed ID: 24294538)
1. A Frailty-Model-Based Method for Estimating Age-Dependent Penetrance from Family Data.
Choi YH
J Biom Biostat; 2012 Feb; Suppl 4(1):. PubMed ID: 24294538
[TBL] [Abstract][Full Text] [Related]
2. A frailty-model-based approach to estimating the age-dependent penetrance function of candidate genes using population-based case-control study designs: an application to data on the BRCA1 gene.
Chen L; Hsu L; Malone K
Biometrics; 2009 Dec; 65(4):1105-14. PubMed ID: 19210733
[TBL] [Abstract][Full Text] [Related]
3. Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene.
Gong G; Whittemore AS
Genet Epidemiol; 2003 Apr; 24(3):173-80. PubMed ID: 12652521
[TBL] [Abstract][Full Text] [Related]
4. On the use of familial aggregation in population-based case probands for calculating penetrance.
Begg CB
J Natl Cancer Inst; 2002 Aug; 94(16):1221-6. PubMed ID: 12189225
[TBL] [Abstract][Full Text] [Related]
5. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of BRCA1 and BRCA2 penetrance.
Chen S; Parmigiani G
J Clin Oncol; 2007 Apr; 25(11):1329-33. PubMed ID: 17416853
[TBL] [Abstract][Full Text] [Related]
7. Estimating the penetrance of pathogenic gene variants in families with missing pedigree information.
Jonker MA; Rijken JA; Hes FJ; Putter H; Hensen EF
Stat Methods Med Res; 2019; 28(10-11):2924-2936. PubMed ID: 30073909
[TBL] [Abstract][Full Text] [Related]
8. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
Marroni F; Aretini P; D'Andrea E; Caligo MA; Cortesi L; Viel A; Ricevuto E; Montagna M; Cipollini G; Federico M; Santarosa M; Marchetti P; Bailey-Wilson JE; Bevilacqua G; Parmigiani G; Presciuttini S
Eur J Hum Genet; 2004 Nov; 12(11):899-906. PubMed ID: 15340362
[TBL] [Abstract][Full Text] [Related]
9. Estimating successive cancer risks in Lynch Syndrome families using a progressive three-state model.
Choi YH; Briollais L; Green J; Parfrey P; Kopciuk K
Stat Med; 2014 Feb; 33(4):618-38. PubMed ID: 23946183
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2.
Park B; Dowty JG; Ahn C; Win AK; Kim SW; Lee MH; Lee JW; Kang E; Hopper JL; Park SK
Breast Cancer Res Treat; 2015 Aug; 152(3):659-65. PubMed ID: 26195121
[TBL] [Abstract][Full Text] [Related]
11. Penetrance estimates for
Evans DG; Woodward E; Harkness EF; Howell A; Plaskocinska I; Maher ER; Tischkowitz MD; Lalloo F
J Med Genet; 2018 Jul; 55(7):442-448. PubMed ID: 29483236
[TBL] [Abstract][Full Text] [Related]
12. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
Evans DG; Shenton A; Woodward E; Lalloo F; Howell A; Maher ER
BMC Cancer; 2008 May; 8():155. PubMed ID: 18513387
[TBL] [Abstract][Full Text] [Related]
13. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG
Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204
[TBL] [Abstract][Full Text] [Related]
14. Estimating gene penetrance from family data.
Gong G; Hannon N; Whittemore AS
Genet Epidemiol; 2010 May; 34(4):373-81. PubMed ID: 20397150
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
16. Estimating disease risk associated with mutated genes in family-based designs.
Choi YH; Kopciuk KA; Briollais L
Hum Hered; 2008; 66(4):238-51. PubMed ID: 18612208
[TBL] [Abstract][Full Text] [Related]
17. Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics.
Scott CL; Jenkins MA; Southey MC; Davis TA; Leary JA; Easton DF; Phillips KA; Hopper JL
Hum Genet; 2003 May; 112(5-6):542-51. PubMed ID: 12601471
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
19. PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history.
Alarcon F; Bourgain C; Gauthier-Villars M; Planté-Bordeneuve V; Stoppa-Lyonnet D; Bonaïti-Pellié C
Genet Epidemiol; 2009 Jul; 33(5):379-85. PubMed ID: 19089844
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
